Published On: Mon, Sep 12th, 2016

Astrazeneca PLC (AZN) Upgraded at Jefferies Group

Astrazeneca PLC (NYSE:AZN) was upgraded by stock analysts at Jefferies Group to a “buy” rating in a report issued on Monday.
A number of other equities analysts have also commented on AZN. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, May 16th. Shore Capital reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Tuesday, May 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Astrazeneca PLC in a research note on Wednesday, May 18th. Bank of America Corp. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday, May 19th. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, May 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and three have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $37.48.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.20 on Monday. The firm has a market capitalization of $81.47 billion, a P/E ratio of 36.80 and a beta of 0.77. The stock’s 50 day moving average price is $33.30 and its 200-day moving average price is $30.17. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/astrazeneca-plc-azn-upgraded-at-jefferies-group.html

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The firm earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. During the same quarter last year, the business posted $1.21 EPS. The company’s revenue was down 4.0% on a year-over-year basis. On average, equities analysts expect that Astrazeneca PLC will post $2.97 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Monday, September 12th. Stockholders of record on Friday, August 12th will be issued a dividend of $0.44 per share. The ex-dividend date is Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
Several hedge funds and other institutional investors recently bought and sold shares of the company. Dodge & Cox increased its position in Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock valued at $733,558,000 after buying an additional 14,272,518 shares during the last quarter. Primecap Management Co. CA increased its position in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock valued at $368,453,000 after buying an additional 12,095,375 shares during the last quarter. Renaissance Technologies LLC increased its position in Astrazeneca PLC by 14.6% in the first quarter. Renaissance Technologies LLC now owns 5,682,800 shares of the company’s stock valued at $160,028,000 after buying an additional 723,100 shares during the last quarter. JPMorgan Chase & Co. increased its position in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock valued at $65,485,000 after buying an additional 6,027 shares during the last quarter. Finally, Pioneer Investment Management Inc. increased its position in Astrazeneca PLC by 44.6% in the fourth quarter. Pioneer Investment Management Inc. now owns 2,201,690 shares of the company’s stock valued at $74,747,000 after buying an additional 679,014 shares during the last quarter. Institutional investors own 11.71% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for Astrazeneca PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrazeneca PLC and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>